Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Godavari Biorefineries Ltd

| Q3 FY26 Earnings Conference Call

BULLISH SENTIMENT

Report Source

⬤26th Feb 26

Summary : Godavari Biorefineries reported strong Q3 FY26 profitability driven by bio-based chemicals, advancing strategic initiatives, and expressing optimism for green transition growth despite ethanol margin pressures.

Management Perspective positive : We remain positive on the outlook for both the bio-based chemicals and ethanol business given supporting structural drivers. I am very optimistic about the green transition.

Concall Report Analysis & Insights

Business Overview

  1. Q3 FY26 profitability improved significantly with EBITDA growing 14% year-on-year.
  2. Profit before tax (PBT) increased by 152% due to operating leverage and improved product mix.
  3. Bio-based chemical business was a key contributor, with EBITDA margin improving to 7.7% in Q3 FY26.
  4. Consumer brand Jivana achieved INR100 crores revenue in 9 months of FY26.
  5. Ethanol segment experienced some softness, while sugar and cogeneration operated seasonally.

Future Growth Prospects

  1. Advancing capacity additions, debottlenecking, and technology investments for high-margin businesses.
  2. Commissioning a grain-based distillery by next quarter to diversify ethanol feedstock.
  3. Commercializing bio-based butyl acrylate through collaboration with Synthomer.
  4. Pursuing out-licensing partnerships for a novel anti-cancer molecule (US patent granted).
  5. Expanding consumer business distribution and product offerings for long-term potential.

Management Insights

  1. Q3 performance shows strengthening operating fundamentals and improving margins.
  2. Strategic initiatives are translating into improved profitability and margins.
  3. Priorities include disciplined execution, capital efficiency, and scaling high-margin businesses.
  4. The company is committed to innovation, sustainability, and portfolio optimization for long-term value.
  5. Bullish on the green transition and the long-term growth of the ethanol sector in India.

Signs of Skepticism

  1. Management stated they are not 'burning cash' on brand building, which may be questioned for competitive consumer markets.
  2. Specific numbers for brand investment were not provided, only a vague 'single digit crores' figure.
  3. The explanation for the exceptional write-off was brief, referring to a previous call for details.

Risk Factors

  1. Uncertainty around future feedstock availability and evolving blending mandates for ethanol.
  2. Ethanol margins are under stress due to rising cane costs and unchanged ethanol prices.
  3. Potential delays in equipment receipt for new facilities, impacting commissioning timelines.
  4. Government policy on ethanol pricing and incentives for flex fuel vehicles remains a concern.

Good To Know

  1. Incorporated Sathgen Therapeutics LLC in the US to market IP and pursue out-licensing for cancer molecule.
  2. DME to CO2 technology initiative is progressing with pilot plant activities underway.
  3. Secured a US patent for a novel anti-cancer molecule targeting Triple Negative Breast Cancer.
  4. Collaboration with Synthomer to commercialize bio-based butyl acrylate using bio-based butanol.
  5. The company aims to achieve 3x EBITDA by FY29, with 75% capex for bio-based chemicals and 25% for ethanol.

Key Drivers

  1. Grain-based distillery commissioning soon.
  2. Bio-based chemicals expansion continues.
  3. Anti-cancer molecule out-licensing.
  4. Increased ethanol blending mandates.

Key Analyst Discussions

Competitive Environment

  1. Company's 'right to win' in cancer research is innovation-led, frugal investment, and strong chemistry/biology.
  2. Consumer brand strategy focuses on value-added products and price stability in a competitive market.
  3. Working with customers to advance lower carbon footprint and substitute fossil-based products.

Market Trends & Consumer Behavior

  1. Government is expected to increase ethanol blend percentages and incentivize flex fuel vehicles.
  2. Growth in the auto sector over the next 10 years will drive increased petrol and E20 blend consumption.
  3. India achieved E20 blending target five years ahead of schedule, enabling bolder future targets.

Financial Highlights

  1. Capital allocation strategy prioritizes bio-based chemicals (75%) over ethanol (25%) for capex.
  2. Rising cane prices have increased pressure on ethanol margins, which remain positive.
  3. Exceptional write-off in Q3 was due to additional harvesting/transport costs and new labor code provision.
  4. The company aims for INR3,000 crores top line with 10-11% EBITDA margin by 2029.

Product Composition

  1. Mitigating feedstock risk by adding maize/grain-based ethanol facility for multi-feedstock flexibility.
  2. Bio-based specialty chemicals contributed 62% to the chemical basket in 9M FY26.
  3. Strategy is to introduce bio-based specialty chemicals to reduce imports or sell overseas.
  4. Developing dimethyl ether as an energy substitute for diesel/LPG, currently in pilot trials.

Strategic Considerations

  1. Managing feedstock and policy risks through multi-feedstock flexibility and ENA capacity.
  2. Balance sheet discipline maintained by optimizing product mix based on economics.
  3. Long-term strategy involves continuous innovation, co-creation with customers, and portfolio optimization.
  4. The company has a continuous pipeline of new bio-based products and cancer biology molecules.